The pandemic drove telehealth usage, but it has challenges that might prevent doctors from prescribing new therapies, said Doug Long, MBA, vice president, industry relations, IQVIA.
The pandemic drove telehealth usage, but it has challenges that might prevent doctors from prescribing new therapies, said Doug Long, MBA, vice president, industry relations, IQVIA.
Transcript
What impact did the pandemic and the shift to telehealth have on the growth of the specialty pharmacy market?
Well, first of all, COVID[-19] created telehealth. It barely existed prior to [COVID-19], and in the early stages of COVID-19, telehealth reached 15% of the medical claims. Now, it's down to 4%. So, it's seeking its level right now.
The handicap on telehealth is they don't have access to the labs and the vitals and things that make doctors comfortable with prescribing new therapies. So, that's the challenge that telehealth is going to have.
Saying that, it really depends on what specialty you're talking about—how relevant telehealth is—because particularly in mental health now, it's a huge thing in mental health.
Sarcoma Care: Biomarker Advancements Shape the Future
October 24th 2024At the regional Institute for Value-Based Medicine® event in Boston, Vinayak Venkataraman, MD, medical oncologist at Dana-Farber Cancer Institute and Harvard Medical School, was a panelist for the discussion, “Recent Advancements in Identifying Predictive Biomarkers for Sarcomas."
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Recognizing Symptoms of Myeloproliferative Neoplasms and Clinical Trial Challenges
October 24th 2024There can be a delay in diagnosis of myeloproliferative neoplasms as the symptoms of the diseases can be variable and common, such as fatigue, migraines, and difficulty concentrating, explained Ruben Mesa, MD, of Atrium Health.
Read More
The Latest in New and Emerging Therapies in Schizophrenia: Dr Megan Ehret
October 22nd 2024In addition to Cobenfy being approved for schizophrenia, there are other drugs with novel mechanisms being studied that may mean combination therapies or, at least, more options for patients in the future.
Read More